Jaraa'idJaraa'id
Notification Show More
Latest News
Hong Kong fire forces 3,400 people to evacuate
Asia
COVID pandemic erased gains in early autism identification -US report
United States
Gemfields full-year profit rises 2% on record ruby, emerald sales
Africa
France postpones King Charles’s state visit as pension protests intensify
Business
Marc Marquez doesn’t think Honda have turned the corner yet – ‘We are not contenders today’
Sports
Aa
  • Home
  • Local News
  • Africa
  • United States
  • Europe
  • Asia
  • Sports
  • Videos
  • Live Score
  • More
    • Business
    • Market Data
      • Stocks
      • Commodities
      • Cryptocurrency
      • Forex
    • Weather
Reading: Economists warn of costs if US Medicare covers new obesity drugs
Share
Aa
Jaraa'idJaraa'id
  • Somalia
  • Africa
  • United States
  • Europe
  • Asia
  • Business
  • Sports
  • Videos
Search
  • Home
  • Local News
  • Videos
  • World
    • Africa
    • United States
    • Europe
    • Asia
  • Market Data
    • Stocks
    • Commodities
    • Cryptocurrency
    • Forex
  • More
    • Sports
    • Business
    • Weather
    • Live Score
Have an existing account? Sign In
Follow US
Jaraa'id > Asia > Economists warn of costs if US Medicare covers new obesity drugs
Asia

Economists warn of costs if US Medicare covers new obesity drugs

News Room
Last updated: 2023/03/11 at 1:56 PM
News Room Published March 11, 2023
Share
SHARE

The cost of expanding US Medicare prescription drug coverage to pay for expensive, new obesity medications could be catastrophic, health economists warned in a report published on Saturday (Mar 11).

Big-selling diabetes drugs have been repurposed as obesity treatments after demonstrating weight loss of more than 20 per cent in clinical trials. While they are far more effective than older drugs, lifetime use might be required to keep lost weight off.

Once-weekly injections of Novo Nordisk’s Wegovy, for example, cost more than US$13,000 per year in the US after rebates and discounts. Mounjaro from Eli Lilly and Co, expected to gain US approval for obesity next year, retails at US$1,540 for a one-month supply for diabetes.

Presently, Medicare is forbidden by law from paying for antiobesity prescriptions. But should the bipartisan The Treat and Reduce Obesity Act get reintroduced and passed by Congress, Medicare will be compelled to cover drugs for weight loss.

Health economists writing in The New England Journal of Medicine estimate that if 10 per cent of Medicare recipients with obesity diagnoses used prescription weight loss drugs, annual part D spending would be US$26.8 billion for Wegovy compared with US$1.32 billion for a generic version older Qysmia from Vivus Inc.

That amounts to nearly 20 per cent of the total 2019 Medicare Part D spending, Khrysta Baig of Vanderbilt University School of Medicine and colleagues said.

“The burden of obesity and obesity-related conditions is unquestionably high, but the value of Medicare coverage of antiobesity medications remains unclear,” they said, adding that more research is needed to know whether weight loss induced by these drugs translates to better long-term health outcomes.

The Medicare health program covers more than 60 million Americans, most over age 65. The authors point out that many people in the program have already incurred the health problems associated with long-term obesity, unlike younger populations typically included in clinical trials.

Obesity prevalence in the United States is 41.5 per cent among adults aged 60 and older, according to the Centers for Disease Control and Prevention.

The influential Institute for Clinical and Economic Review (ICER) has said the annual price of Wegovy would need to decrease to US$7,500 to US$9,700 for it to be cost effective compared with lifestyle modification alone. Even at that price range, it still would not be cost-effective compared with generic Qysmia, ICER said.

“Given the outstanding questions about the benefits of these drugs for Medicare beneficiaries, it would be prudent for Congress and CMS (the Centers for Medicare & Medicaid Services) to fully consider tradeoffs before passing legislation of this magnitude,” Baig said.

Read the full article here

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
I have read and agree to the terms & conditions
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
News Room March 11, 2023
Share this Article
Facebook Twitter Email Print
What do you think?
Love0
Sad0
Happy0
Sleepy0
Angry0
Dead0
Wink0
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular News
Asia

Hong Kong fire forces 3,400 people to evacuate

News Room News Room March 24, 2023
COVID pandemic erased gains in early autism identification -US report
Gemfields full-year profit rises 2% on record ruby, emerald sales
France postpones King Charles’s state visit as pension protests intensify
Marc Marquez doesn’t think Honda have turned the corner yet – ‘We are not contenders today’
Trump warns of ‘potential death & destruction’ if he is charged in hush-money case
Rwanda has to investigate killings of opposition members
Divided opinion in Indonesia after Jokowi bans senior officials from staging events to break fast
- Advertisement -
Ad imageAd image

You Might also Like

Asia

Hong Kong fire forces 3,400 people to evacuate

March 24, 2023
Asia

Divided opinion in Indonesia after Jokowi bans senior officials from staging events to break fast

March 24, 2023
Asia

Indonesia fuel depot fire death toll rises to 33

March 24, 2023
Asia

Hong Kong government announces measures to lure wealthy family offices

March 24, 2023
  • Somalia
  • Africa
  • United States
  • Europe
  • Asia
  • Cryptocurrency
  • Forex
  • Stock Market

About US

Jaraa'id is your one-stop website for the latest global and local news and updates, follow us now to get the news that matters to you.
Quick Link
  • Privacy Policy
  • Terms of use
  • Press ReleaseSubmit
  • Advertise
  • Contact
Top Sections
  • Business
  • Sports
  • Videos
  • Market DataLive
  • Weather

Subscribe US

Subscribe to our newsletter to get our Latest articles instantly!

I have read and agree to the terms & conditions

2023 © Jaraa'id. All Rights Reserved.

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?